Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
This is a critical situation demanding immediate, decisive, and ethical action. Patient safety and regulatory integrity must precede financial preservation. Delaying disclosure is legally and ethically indefensible, particularly given the severity of the side effect (liver failure).Read the full answer
As CEO, I would not wait six months and I would not let the board delay disclosure while patients remain exposed to an unreported serious risk. I would treat this as a patient-safety, regulatory, legal, and trust crisis—not merely a financial-risk issue. My guiding decisions would be: Patient safety comes first.Read the full answer